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ABSTRACT 
 
            KEY WORDS – EARLY DETECTION,COPD,ASYMPTOMATIC SMOKERS,PFT 
AIM OF THE STUDY: 
Smokers with suspected COPD seek medical attention when they become  dyspnoeic  on 
mild to moderate exertion, but by than half of the ventilator  reserves are lost irreversibly. 
Hence it seems logical to diagnose COPD early before development of significant 
symptoms. Since smoking cessation in COPD is found to reduce rapid decline of 
ventilator  function in smokers and  to make an attempt to quit smoking in south Indian 
population 
MATERIALS AND METHODS: 
Patients attending outpatient  department at MGM Govt. Hospital attached to KAPV 
Govt. Medical College , Tiruchirappalli  
EASY ONE spirometer 
TYPE OF STUDY: 
Unicentric   Prospective  description study. 
USEFULNESS OF THE STUDY: 
Chronic obstructive pulmonary disease (COPD) is a major case of chronic morbidity and 
mortality. Third  leading cause of death in 2020Smoking cessation will improve quality 
of life and decrease the morbidity and mortality  
 
 
 
 
INTRODUCTION 
Among Non communicable diseases COPD is emerging as one of 
the leading cause of mortality in INDIA. The incidence and prevalence of 
COPD is increasing throughout the world with more population is 
reaching the age group,above 60 years at which the disease normally 
develops. 
COPD is now ranked sixth among the leading cause of death 
worldwide according to 1990 world burden of disease study. It is also 
projected to become third leading cause of mortality by 2020.
1
 
Prevalence of COPD in people aged more than 30 years in India is 
2.7% in females and 5% in males according to meta analysis of 
population based study by Jindal SK et al.
 2
 
Smoking not only causes health hazard to individual also produces 
environmental tobacco smoking (ETS) to non smokers as it contaminates 
the atmosphere 
Among various causes of COPD tobacco smoking is leading cause. 
Smokers often ignore the early symptoms of COPD such as cough and 
sputum production. Even treating physician often ignores it as normal in 
smokers.  
 
 
Smokers seek physicians attention only when they develop mild to 
moderate exertional  dyspnoea  by the time 50% of their ventilatory 
reserves lost. The loss is also irreversible. 
3
 
Therefore it is necessary to diagnose COPD incidence earlier in 
smokers . Sothat measures such as smoking cessation can be initiated at 
appropriate time and preserve the ventilatory capacity in smokers.
4
 
Post bronchodilator Spirometry remains the gold standard   for diagnosis 
and follow up of COPD patients .
5
 
Air flow limitation is the hallmark of COPD. It is most objectively 
measured and reproduced by spirometry 
Spirometry is best standardized and according to GOLD criteria it 
can categorize the severity of disease. 
This study is done to detect COPD earlier in south Indian smokers 
and to analyze the association of age of onset, duration, pack years, 
smoking index and severity of disease according to GOLD criteria. 
                           
  
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
  
 
 
REVIEW   OF  LITERATURE 
Smoking cessation dates back to 1975 when Norwegean tobacco 
act banned all forms of advertisements.
6
 
  The relationship between cigarette smoking and decline in lung 
function was studied by Fletcher and Peto et al in 1977 and the same was 
published in British medical journal in 1977 as the natural history of 
chronic airflow obstruction. 
They published the graphical representation of smoking and smoking 
cessation and effects on lung function.
7
 
The earlier 1977 Fletcher and Peto curve demonstrated slower 
decline in lung function during early stages. The curve still holds land 
mark in understanding the  natural history of COPD. 
  Screening for Early detection of COPD among smokers started in 
Finland in 1998 through program  for chronic bronchitis and COPD. In 
this program  early detection of COPD using spirometry was done and 
patients were followed by smoking cessation clinics.
8
 
In Swedes   study, 40 to 55-year-old inhabitants who smoked and 
symptomatic or non symptomatic COPD were Invited to participate  in 
the study. The participants were given placards and subjected to have 
spirometry. Of the approximately 5332 eligible smokers in that area, only 
512 (9.6%) responded. Out of which 73% had a normal spirometry and 
 
 
27% had COPD. In this study only 40-55 years age group included. They 
also included already existing COPD patients. 43% males and 57% 
females participated in this study but female smokers are low in our 
country like India. 6 out of 147 participants had asthma during the study. 
Bronchial asthma patients are not excluded from study. Stralelis G, et al 
designed  this  study to assess a method to detect COPD at an early 
stage.
9
 
            Kohansal, Martinez-Camblor, Agustı´, et al. done  The 
Framingham Offspring cohort  which was started between 1971 and 1975 
includes 5,124 males and females all of which had reliable spirometric 
measurements and appropriate clinical information according to internal 
National Heart, Lung, and Blood Institute–National Institutes of Health 
standards smoking increases the rate of reduction of  FEV1 in both males 
and female. They   also established that there is considerable variability in 
the rate of decline of pulmonary function in constant smokers, both in 
males (from 8 to 63 ml/yr) and females (from 14 to 49 ml/yr). However, 
this is the first time that a huge cohort of both males and females, with a 
extensive age range, is followed for up to 26 years to depict pulmonary 
function changes from adolescence to Old  age in healthy never-smokers 
and to investigate the effects of smoking and smoking cessation. the 
results were published in American journal of respiratory and critical care 
medicine vol 180 2009. Limitations of this study are only four spirometry 
 
 
values available for each participant and several confounders like 
occupational exposure and environmental tobacco smoke were not 
excluded.
10
 
Gorecka, et al from Poland demonstrated that diagnosis of 
Airflow   limitation shared with smoking cessation advice   increased 
smoking cessation  rate. High risk population screening for COPD have 
been investigated and implemented in Poland in this study out of 11027 
smokers more  than 40 years screened for airflow obstruction was found 
in 24.3% of smokers.
4
 
 In Lung health study (LHS), a large   multi-centric study 
conducted in USA and Canada, spirometry screening of more than 73,000 
smokers aged 35 to 60 years was  performed  in 10 centers. Air flow 
limitation was noted in 21.8% to 35.7% (mean 25%) cases and severe 
obstruction (FEV1 <50% of predicted) was seen in 5% of total cases.  In 
LHS study symptomatic smokers were also included. Hence prevalence 
was high in that group.
11
 
     Zielinski et al performed a study called  “Know the age of your lung 
study group”  evaluated  the usefulness of mass spirometry in detection of 
airflow limitation in high risk smoking population above 39 years of age. 
Outof  11027 subjects were screened with mean age of 51.8 ± 12.5 years. 
The average smoking history of 26.1 ± 16.8 pack-years (equal to smoking 
index  of 522±336). In general obstruction was noted in 24.3% cases. 
 
 
Mild obstruction was seen in 9.5%, moderate in 9.6% and severe in 5.2% 
subjects. Analysis of sub-groups in the study threw light that obstruction 
seen in 30.6% of smokers above
  
 40 
years of age. This  correlate with smoking history of more than 
  
10
 
 
pack years (equivalent to smoking index 200) .In contrary only 8.3% of 
smokers below 40 years and having smoking history of less than 10 pack 
years (equivalent to smoking index  200).
12
 
P.L. Enright, M. Studnicka, J. Zielinski, from The University of 
Arizona, Tucson, USA conducted study using handy or office spirometer 
along with primary care physicians for early detection of COPD in 
smokers. They have demonstrated that recent spirometers are weightless, 
less space occupying, easy to handle and can be used by primary care 
physicians.  Spirometry to detect and manage COPD and asthma in  the   
primary care setting study also done according to GOLD criteria. 
FEV1/FVC or FEV1/FEV6 ratio is taken as reference for airflow 
obstruction detection. So our study we utilized microprocessor enabled 
spirometer. Microprocessor enabled spirometer can be connected to 
computer to analyze the data as done in the above study.
13
 
In North India Barthwal MS,and  Singh S studied the occurrence of 
COPD in high risk population in Military institutions in Pune, Maharastra 
using office spirometry.  They have analyzed 460 patients and found air 
flow obstruction in 12.6% of smokers. The sample size for this study has 
 
 
been calculated based on the data available from foreign authors. They 
also pointed out that prevalence of COPD increases as age advance. In 
this study they used 40 years as age cut off. With the available data from 
India we planned to conduct the study in South Indian population. In our 
study sample size was calculated based on this study. So prevalence of 
12.6% has been used to calculate sample size.
14
 
In DIDASCO study which was designed to analyze diagnostic 
criteria for COPD and asthma. They have divided the patients into two 
groups .  One group was screened with spirometry after inhaled steroids 
and another with beta agonist. 
They screened patient between 35-70 years. GOLD criteria was 
used to categorize the patients for airflow obstruction. Patients were 
analyzed for airflow reversibility of 12% from pre to post 400 mcg 
inhaled salbutamol in FEV1.Patients with  reversible airflow limitations 
were diagnosed as asthma. This study clearly demonstrated that 
spirometry can be used to detect obstructive lung disease in general 
practitioners office using FEV1/FVC ratio as reference value. This study 
also thrown light that 42% of patients with obstructive disease could  not  
have been diagnosed with out spirometry. Thus they recommended 
routine use of spirometry for obstructive lung disease diagnosis and 
follow up.
15
 
 
 
 
In India Moorthy and Sastry published the report called  burden of 
diseases in India.In that report on the economic  burden of COPD in our 
country pointed out that  prevalence of obstructive lung disease is high 
compared to north India. Prevalence in Madras (Chennai) is 10.2%.  So it 
is rationale to have sample size of around  12%  prevalence for our study. 
That   comes roughly 160-170 subjects. 
16
 
 
SMOKING  INDEX :  
In countries like India smoking of tobacco varies between 
individuals. It may be either cigarette or bidis. Quantity or number also 
differs.  
Cigarettes are 10 per pack and bidis 15-24 per pack. So quantum of 
smoking by pack years is not applicable to our country. Thus evolved 
smoking  index. Which  is expressed as number of cigarettes/bidis 
smoked per day multiplied by years of smoking. It is not the amount of 
tobacco present   per bidi or cigarette but total particulate matter (TPM) 
matters when degree of exposure is concerned. TPM per bidi is 23-30 mg 
which is equal to nicotine content of 1.72-2.05 mg. in cigarette TPM is 
21.16-21.94 mg and nicotine content is 1.04-1.21 mg. mean while as we 
compare pack year and smoking index  for example 1 bidi per day for 10 
years is same as 10 bidis / day for 1year. It clearly indicates the amount of 
exposure. 
 
 
SI is also categorized as mild 100, moderate 100-300 and severe 
300 from Lung India, smoking index- a measure to quantify cumulative 
smoking exposure,1988.
17 
 
 
With all these literature review the original curve of Fletcher and 
Peto has been modified and published as follows in natural history of 
obstructive lung disease. The earlier curve predicted that lung damage 
occurs at old age but it was proved wrong. The newer concept is damage 
to lung volumes in smokers occur at much early as predicted by 
spirometry. 
   
 
 
 
 
This modified curve of Fletcher and Peto clearly shows that 
smoking cessation started at earlier age is more beneficial than at later 
age in regard to obstructive lung pathology. The curve also gives clear 
evidence that smoking cessation started before forty  years is more 
beneficial than later. So we included from age 25 years in this study. Any 
intervention that is done after half of lung volume is lost is not useful for 
improving the quality of life in COPD patients. So our aim is to identify 
the smokers at risk in earlier stage so that they can be motivated for 
smoking cessation. 
                               
 
 
 
 
 
 
 
 
 
 
 
 
                              TOBACCO  SMOKING 
Half of all regular cigarette smokers will eventually be killed by 
their habit.18. Death due to tobacco is one million in developing 
countries. This will increase to 10 million in 2020.
19
 
Smoking causes increase in incidence of death due to carcinoma 
lungs, respiratory tract carcinoma, COPD and   corpulmonale. 
It also advances the incidence of coronary artery disease and 
cerebrovascular disease related death. 
Smoking cessation decreases the morbidity and mortality related to 
disease of tobacco. 
Smoking habit starts for psychosocial reasons like  parental  
smoking, peer stress, feel of independence, rebelliousness usually during 
adolescence.
20
 
Once started pharmacological aspects of nicotine makes it as habit 
which causes psychological advantages in mood of an individual and 
causes the habit to persist. 
 
 
Rusell described smoking as “  probably  the most addictive and 
dependence producing form of object specific self gratification known to 
man”.21 
In developing countries the pattern of smoking is different from 
developed world. 50% of men and only 10% females smoke in 
developing countries. Asia is accounting for about 50% 0f world’s 
cigarette smoke. 
SAFE   CIGARETTES !! 
        NO CIGARETTE IS SAFE including substitutes like synthetic 
tobacco, glycerol particles and modified cellulose.
22
 
  
 
 
HEALTH EFFECTS OF SMOKING 
 RESPIRATORY SYSTEM:  
COPD, carcinoma of lungs, carcinoma of upper respiratory tract 
particularly laryngeal carcinoma.
18
 
CARDIOVASCULAR SYSTEM:   
Incidence of death related to myocardial infarction is 2-3 times 
higher in smokers. Cerebrovascular events like stroke,  sub arachnoid   
hemorrhage  is also 2-3 times higher . Almost 90% of patients are 
smokers when peripheral vascular disease is concerned.
23, 24
 
GASTROINTESTINAL SYSTEM:  
Peptic ulcer disease, carcinoma esophagus and Crohns disease have 
strong association with smoking.
25
  
Carcinoma   stomach and pancreas also significant in smokers. 
GENITOURINARY SYSTEM: 
 Increases the risk of   infertility, renal and bladder cancer in men. 
In women cervical carcinoma is 4 times more common than non 
smokers.
26
 
 
 
 
MISCELLANEOUS SYSTEMS:  
 Cadmium in tobacco causes cataract 
Post menopausal   fractures due to reduced bone density 
Palmoplantar  pustulosis and premature facial wrinkling .
27
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          Diagrammatic representation of health effects of smoking  
 
 
 
 
MECHANISM OF HARM 
1. SMOKERS 
2. NON SMOKERS 
IN SMOKERS:  
LUNGS:-  
Toxins like polycyclic aromatic compounds, nitrosoamines, and 
radioactive polonium causes the following  effects that leads to various ill 
effects in lungs.
30
 
 
 
BRONCHITIS  
EMPHYSEMA 
CARCINOMA 
DECREASES  
ALPHA 1 ANTI 
TRYPSIN LEVELS 
RELEASE OF 
ELASTOLYTIC 
ENZYMES FROM 
NEUROPHILS 
INCREASES 
PULMONARY 
EPITHELIAL 
PERMEABILITY 
DECREASES 
NITRIC ACID 
LEVELS 
 
 
CARDIOVASCULAR: - increase in systemic vascular permeability to 
lipids causes atherosclerosis.
30                             
 
 
The above chain of events occur in smokers that leads to myocardial 
infarction, cardiac arrythmias and sudden cardiac death. 
NON SMOKERS:- it is variously known as Passive smoking, second 
hand smoking or environmental tobacco smoking.  
  
INCREASED CARBOXY 
HEMOGLOBIN 
DECREASED OXYGEN 
CARRYING CAPACITY 
INCREASED 
CATECHOLAMINES 
PLATELET STICKINESS 
AND AGGREGATION 
MYOCARDIAL 
INFARCTION 
 
 
EFFECTS DUE TO PARENTAL SMOKING 
1.Low birth weight 
2.Sudden infant death 
3.Pneumonia and bronchitis in children 
4. Decreased lung function  
5.Asthma in children 
6. Increased risk of childhood cancers 
7. Learning difficulties in children.
31,32
 
EFFECTS DUE TO ENVIRONMENTAL SMOKING 
1. Chest colds and loss of work days 
2. Increased risk of lung cancer in spouse 
3. Worsening of angina 
4. Increased rate of death from ischemic heart disease 
5. Decreased productivity and economic burden due to illness among 
workers exposed to environmental tobacco smoke .
33,34
 
SMOKING CESSATION 
   Health education regarding ill effects of smoking to general 
population, health professionals and politicians is the corner stone.
35
 
 
 
Strict laws like Norwegian tobacco act 1975 should be implemented to 
control smoking. 
Advertising the financial savings of the individuals who quit 
smoking is also important. This is done in Norway during 1975 – 1980 
Which brought predictable drop in smoking . The Norwegian council on 
smoking and health also made legislation that offered jobs in asbestos 
industry only to non smokers. They also raised the price as well as tax on 
cigarretes. So multi deciplinary approach alone will bring down the 
incidence of smoking. Early detection of air flow obstruction in smokers 
offers important   tool to educate the community. 
 
             
  
 
 
      CHRONIC OBSTRUCTIVE PULMONARY DIASEASE 
Definition : chronic obstructive pulmonary disease is defined   
according to GOLD criteria as airflow limitation that is not fully 
reversible.
5
 
COPD includes the following 
1. EMPHYSEMA: Anatomically defined condition in which there is 
destruction and enlargement of alveoli 
2. CHRONIC BRONCHITIS: Clinically defined disease which is 
associated with chronic cough and phlegm 
3. SMALL AIRWAYS DISEASE:  Characterized by narrowing of Small 
bronchioles. 
Criteria  to diagnose COPD is presence of chronic airflow obstruction. 
RISK FACTORS 
1. Cigarette smoking:  Association   between cigarette smoking and 
COPD is proved absolutely. There is also correlation between FEV1 
and pack years of smoking in general population. 
 
 
 
2. AIRWAY RESPONSIVENESS  
Two  hypothesis has been formulated based on airway responsiveness 
of patients with COPD 
i. DUTCH HYPOTHESIS: It states that bronchial asthma, chronic 
bronchitis and emphysema are variations of same disease. These 
are modulated by genetic and environmental factors to produce 
these distinct disease patterns. 
 
 
ii. BRITISH HYPOTHESIS: It states that asthma and COPD are  
two different disease entities .Asthma is due to allergic 
phenomenon and COPD is due to smoking related inflammatory 
disease. 
Validation of these hypothesis awaits analysis of predisposing 
factors like genetic and environmental factors. 
3. RESPIRATORY INFECTIONS: This entity  awaits to be proven 
since there is no data available to correlate. These are now important 
cause of acute exacerbations 
4. OCCUPATIONAL EXPOSURE: The following occupational 
exposures have been suggested as risk factors for COPD Coal mining, 
cotton mill dust and gold Mining. 
5. AMBIENT AIR POLLUTION: Urban living and biomass 
combustion in rural areas  are  proposed but not proven. 
6. PASSIVE OR SECOND HAND SMOKE EXPOSURE: Maternal 
smoking is associated with adverse neonatal outcome like low birth 
weight, reduced lung growth and reduction in post natal lung function. 
7. GENETIC FACTORS:  
     i. Alpha one antitrypsin deficiency: Many protease inhibitors have 
been postulated among them  
 
 
    M allele is most common associated with normal a1AT 
    S allele with slightly reduced a1AT  
    Z allele with   severely  reduced a1AT  
PiZ is known to be either individual with one Z and one null allele 
or two   Z allele and it is the common form of a1AT deficiency. 
 COPD occurs in earlier age in a1AT deficiency smokers than non 
smokers.
36
 
Other genes responsible for COPD are MMP12  and  HHIP.
38
 
NATURAL HISTORY OF COPD 
The association of cigarette smoking and lung function depends on 
duration  of smoking, intensity of smoking, baseline pulmonary function 
of individual and environmental factors. 
Reduced  levels of FEV1 is closely associated with mortality in 
COPD.  
  
 
 
 
GRAPHICAL REPRESENTATION OF NATURAL HISTORY OF 
COPD ON FEV1 TRACKING 
 
 
          Early interventions like smoking cessation in young age  will  
provide more morbidity and mortality benefits than measures done after 
significant decline in pulmonary function.  
Genetic and environmental factors play a crucial role along with 
smoking. 
 
 
 
PATHOPHYSIOLOGY 
  Airflow obstruction in the form of persistent reduction in forced 
expiratory flow rate is classical finding in patients with COPD. 
 AIRFLOW OBSTRUCTION: 
Also known as airflow limitation which is measured by spirometry 
uses forced expiratory maneuvers. Key parameters obtained are FEV1 
and FVC. Patient with COPD have chronic reductions in FEV1/FVC   
ratio. 
Post bronchodilator FEV1 will show improvements   up to 15% 
which is helpful in differentiating from asthma. In asthma there will be 
larger response to inhaled bronchodilator. 
    In initial stages of COPD the airflow abnormality is evident at or 
below the functional   residual   capacity. It gives scooped out appearance 
to lower part of flow volume loop. In advanced disease the curve assumes 
reduced expiratory flow compared to normal 
HYPERINFLATION: 
     It compensates for airflow limitation but has deleterious effects on 
lung function by flattening diaphragm. 
 
 
 
Diagrammatic representation of effects of hyperinflation on lung function 
                                                                           
GAS EXCHANGE: 
      PaO2 falls below normal range only when FEV1 is less than 50% 
of predicted. Rise in PaCo2 occurs only with FEV1values below 25%   of  
predicted. 
     Ventilation perfusion mismatch occurring in COPD is 
characteristic as it is non uniform. 
DECREASED ZONE 
OF OPPOSITION 
• POSITIVE ABDOMINAL 
PRESSURE DURING 
INSPIRATION IS NOT APPLIED 
TO CHEST WALL 
• REDUCED RIB CAGE 
MOVEMENT AND INSPIRATION 
SHORTENING OF 
DIAPHRAGMATIC 
MUCLE FIBRE 
• LESS CAPABLE OF GENERATING 
INSPIRATORY PRESSURES 
LAPLACE LAW 
p=2t/r 
• REDUCED RADIUS-r 
• REQUIRES GREATER  
TENSION-t  
• TO DEVELOPE 
TRANSPULMONARY 
PRESSURE-p 
FLATTENING OF   
DIAPHRAGM 
 
 
 
     Supplemental   oxygen is useful in treating hypoxemia due to 
COPD because shunting is minimal. 
   
                                 PATHOLOGY 
LARGE AIRWAYS: Mucous gland  enlargement , goblet cell 
hyperplasia and squamous cell  metaplasia of bronchial mucosa 
SMALL AIRWAYS:  Airways  <2 mm are major sites for resistance in 
COPD. Reduction   in surfactant secreting type 2 cells increases surface 
tension. 
LUNG PARENCHYMA: Destruction of respiratory bronchioles, alveolar 
ducts and alveoli results in reduction in gas exchanging air spaces in 
emphysema. Types of emphysema are cenriacinar and panacinar. 
PATHOGENESIS 
Fibrosis and collagen accumulation around small airways is 
significant contributor. Schematic representation of chain of events that 
occur in smokers and leads to COPD is as follows 
 
 
 
 
 
Figure showing the pathogenesis of emphysema 
 
 
Prominent steps are 
1. Smoking causes recruitment of inflammatory cells to airways 
2. Elastase and antielastase hypothesis 
3. Extracellular matrix proteolysis 
 
 
4. Cell death  
5. Ineffective repair 
 
CLINICAL PRESENTATION 
      Majority of smokers are asymptomatic until 50% of their lung volume 
is lost. 
Cough, sputum production and  exertional  dyspnea are common 
symptoms in COPD. 
Patients usually have symptoms years before and come for medical 
attention only after worsening. 
Physical examination show prolonged expiration and expiratory 
wheeze.  
Pink puffers or emphysematous   patients are thin and non cyanotic 
at rest. 
Blue bloaters or chronic bronchitis patients are heavy and cyanotic  
Hoovers sign- in advanced disease there is inward  movement  of rib 
cage during inspiration. 
In severe obstruction the  patient  will  assume  tripod position. 
 
 
 
 
LABORATORY FINDINGS 
1. Pulmonary function testing. 
Pulmonary function tests are defined as a series of tests both invasive 
and non invasive  done with standardized equipment . 
They are used to identify and quantify many structural and functional      
abnormalities of the respiratory system . 
 
These include 
1. Spirometry 
 
2. Lung volumes by helium dilution or by body plethysmography 
         - Tests for ventilatory function 
 
3. Peak Expiratory flow rate using breathometer 
 
4. Pulse oximetry 
         -  Bedside tests 
 
5. Ventilation –Perfusion scan (V/Q scan) 
 
 
 
6. Diffusing capacity for carbon monoxide 
       -  Tests for diffusion 
 
7. PI max and PE max 
        -   Test for respiratory muscle function 
 
8. Arterial blood gases  
        
  9 . Bronchial challenge tests 
 
10. Exercise test 
 
11. Polysomnography  
       1.  Test for sleep related disorder 
12. Other tests  
1. Chest radiograph 
2. Computed tomography of chest 
3.  a1AT levels in serum 
4. Molecular genotyping of PI alleles (M,S ,and Z) 
     
 
 
 
 
 
GOLD CRITERIA 
 
 
 
 
 
 
 
 
GOLD: Global Initiative for Obstructive Lung Disease requires 
FEV1FVC ratio less than 0.7 post bronchodilator. 
CRITERIA FOR COPD SEVERITY: 
1. Mild COPD         -   FEV1/FVC <0.7  and  FEV1p> 80% 
2. Moderate COPD  -  FEV1/FVC <0.7 and FEV1p 50% - 80%  
3. Severe COPD      -  FEV1/FVC <0.7 and FEV1p 30% - 50% 
4. Verysevere COPD- FEV1/FVC <0.7 and FEV1p< 30% 
                                                    or 
                               FEV1p <50% and chronic respiratory           
failure. 
In our study after identifying the patients with COPD the 
severity  is assessed according to above guidelines. 
 
 
 
 
 
 
 
 
 
 
TREATMENT 
 1.  General measures like smoking cessation, oxygen therapy.  
2.  Bronchodilators – beta agonist, anticholinergics, inhaled  
 corticosteroids 
3. Oral  glucocorticoids 
4. Theophylline 
5. N-acetyl cystine 
6. a1AT augmentation therapy 
7. Pulmonary rehabilitation 
8. Lung volume reduction surgery 
9. Lung transplantation 
10. Mechanical ventilatory support .
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Figure – Inhalation therapies in COPD according to GOLD guidelines 
 
 
 
 
 
 
 
 
 
SPIROMETRY 
HISTORY 
1800 Hutchinson developed simple water sealed spirometer used 
measure vital capacity 
1930 barach developed kymograph or rotating chart drum that 
displated changes in vital capacity as spirogram. 
1941 Cournand and Richard described MVV 
1947 Tiffeneau described FEV1/IVC ratio as index of airflow 
limitation called Tiffeneau index 
1950 Gaensler used micro along with water sealed spirometer to 
time FVC1950 Comroe,Dubois and others described technique to 
estimate alveolar pressure. 
1950 late , Hyatt used flow volume curve to display air way 
function 
1955 Leuallen and Fowler described maximal mid expiratory flow 
rates  25% and 75% now known as FEF25%-75% 
1960 Wright and Mckerrow started using peak flow meter in 
asthma patients 
 
 
Spirometry is the most commonly performed lung function test . it is 
described as GOLD STANDARD to diagnose COPD by WHO and 
GOLD criteria. 
INDICATIONS FOR SPIROMETRY 
1. To diagnose the presence or absence of lung disease 
2. To quantify the known pulmonary disease severity 
3. To  measure the environmental and occupational exposure effects 
4. To identify the merits and demerits of therapy 
5. To assess the risk factors of proposed surgical procedures in view of     
    pulmonary disease 
6. To evaluate morbidity or impairment for legal or insurance 
evaluation 
7. To evaluate datas for epidemiological and clinical research  in the 
field of lung diseases 
CONTRAINDICATIONS TO SPIROMETRY 
ABSOLUTE 
1. Acute coronary event ,myocardial infarction in last 30 days 
2. Recent thoraco abdominal or ophthalmic surgery 
 
 
3. Recent  Cerebrovascular event 
4. Poorly controlled hypertention 
5. Underlying aortic and cerebral aneurysm 
6.Recent pneumothorax 
RELATIVE 
1. Head ache 
2. Stress incontinence  
3. Confusion 
4. Facial, abdominal and chest pain 
5. Dementia 
 
LUNG VOLUMES AND DEFINITIONS 
The quantity of air that moves in and out the respiratory tract during 
each respiratory cycle is called Tidal volume (TV) 
 
The further volume of air that can be inspired after a normal tidal  
 inspiration  is called Inspiratory  reserve volume (IRV)   
The further volume of air that can be exhaled after a normal tidal 
expiration is called   Expiratory reserve volume (ERV)  
The maximal amount of air that can be exhaled after a maximal 
 
 
inspiration is  called Vital capacity (VC) . VC = TV + IRV + ERV.  
The amount of air that relics in the lungs after   maximal expiration is 
Residul volume (RV) . Even with forceful effort it cannot be expired   
 
The quantity of air that remains in the  lung after maximal inspiration is 
termed as 
 
          Total lung capacity (TLC) . TLC = FRC + TV + IRV = VC + RV  
 
The volume of air exhaled per minute is called Minute volume.  
 
Maximal voluntary ventilation (Maximum   breathing capacity ) 
is the  highest amount  of air that can be exhaled in a 15 second gap by  
voluntary effort. This is uttered as liters per minute by multiplying by 4.  
 
The quantity of air that can be forcefully exhaled in 1 second is 
termed as    Forced  expiratory volume 1 (FEV1) 
 
The maximum amount of air that can be forcefully exhaled   is termed 
as Forced vital capacity (FVC)   
       FEV1/FVC is   expressed as a percentage.  
 
 
 
The standard volume of air that is exhaled during the mid portion of 
FVC is  termed  as Mid expiratory flow (MEF25 - 75)   
 
The peak flow rate during expiration is called as Peak expiratory flow 
rate         (PEFR) -   normal  range is 400-600 L/min 
It is a consistent method of differentiating obstructive 
airway   disorders and restrictive  lung diseases. 
  
 Precise spirometry can only be  performed  with proper training and 
adequate motivation of patients. 
 
 
  
 
 
 
LIMITATIONS 
 
1. It requests a well trained technician and patient support for 
accuracy of test 
 
2. There is a little variability in normal predictive value 
 
3. It should be interpreted in the milieu of a proper history, physical 
examination   and  added diagnostic tests. 
 
 
ADVANTAGES 
 Simple & supportive in reaching diagnosis  
 Used as a  first stride in detecting  lung function abnormalities  &  
 
Answer important questions such as:  
         Is there airflow limitation? If so how severe is it?  
Is there a response to bronchodilator therapy? If so  how  much? 
Is there barrier present down the major airways?  
 
Is it intra or extra thoracic?  
 
 
         Figure – Lung volumes and capacities 
 
 
 
 
      
 
 
 
 
 
 
 
 
 
  
 
 
PERFORMING 
SPIROMETRY  
Preparation  
1. Equipment :  
 Checking for leaks  
 Fresh   mouth  piece 
 Checking   recording equipment  
 Performing calibrations  
 
2. Patient 
 The  height  and weight are measured 
 Any contraindications   should be ruled out 
 The  procedure  is explained to the individual and should be 
demonstrated 
 The person should sit erect and look straight ahead to avoid 
stretching   of trachea. 
 
Basic 
Components 
 Maximal inspiration  
 Maximal expiration ('blast' expiration)  
 
 
 Continued expiration until maximal amount of air is exhaled up to 
residual volume -  at least  a 6 seconds of  exhalation in adults  
 
 Correct  maneuver  
 The exhaled volume should be delivered from the level of 
maximum inspiration with  maximal  exertion.  
 The   maneuver is started immediately with  a  'blast' .  There   
should  be rapid  rise to  peak flow, and the attempt is sustained. 
 The exhalation should continue to the residual volume. ( exhalation 
continued Up to  vital  capacity). 
 
    It should not be troubled by coughing or sneezing.  
   There should not be any leak from mouthpiece   
 
  
 
 
ATS/ERS recommendations are  as  follows:  
 
FVC minimum duration 
 
6 sec ( 3 sec for children) or plateau in the volume time 
 
 curve, subject cannot or could not continue to exhale 
 
FVC end of test criteria 
 
Subject cannot or should not continue further 
 
 exhalation  or the volume time curve shows an obvious  
 
plateau  or  the forced exhalation is of reasonable 
  
 duration 
 
FVC maximum number  
of maneuvers 
 
8, both in adults and children 
 
FVC  maneuver  
 
acceptability  
 
Unsatisfactory start of expiration 
 
Back extrapolated volume > 5% of FVC or 150 ml,  
Whichever is greater 
Coughing which interferes with measurement of  
FEV1 and /or FVC. 
Early termination of expiration  
Valsalva maneuver 
A leak 
An obstructed mouth piece 
Effort that is not maximal 
FVC and FEV1  
 
reproducibility 
 
the largest and second largest FVC and FEV1  
 
should not differ by 150 ml 
 
 
 
 
 
NORMAL VALUES  
The outcome of  Spirometry  are  reported as  absolute 
(measured) values and as predicted percentage of normal values. 
Normal  values  will depend on the individuals age, sex, ethnicity and 
height. There is no universal standardization for normal values and the 
values that differ  from one laboratory to the other.  
  
Thus normal reference values were obtained by performing tests 
in thousands of people based on age, sex, ethnicity and height.  
  
 
  
 
 
 
FACTORS DETERMINING LUNG VOLUMES  
 
 HEIGHT- shorter persons have lesser lung volumes  
 
 GENDER - females have lesser lung volumes than  males  
 
 AGE – lung volume keeps on rising in children, steady in adults and  
as age advances the ERV decreases and  RV,FRC increases . 
 
 ETHNICITY – values vary for Africans,  Asian , and White 
populations  
 
 
  
 
 
Normal value = 80 - 120% of predicted  
      
SPIROMETRY REPORT : typically consists of absolute numerical 
values or graphical depiction of the same or a mixture of both.  
 
Common Numerical Values  
 
 
 
 
-75%  
 
Graphical representation  
 
  - Time - Volume curve  
  - Flow - Volume loop  
 
 
 
 
 
 
 
FEV1 (Forced Expiratory Volume in the first second) is the volume 
expired in the first second of the test .  
 
FEV1%=FEV1/FVC X100.  
 
roughly 80% of all the air is exhaled out in the first second by a healthy 
individual out of their lungs during the FVC exercise.  
 
 FEV1% will be reduced in case of barrier in upper airways.  
 
 
Too high  FEV1%  is  indicative of restriction .  
 
 
OBSTRUCTIVE PATTERN: 
Either  intrathoracic or extrathoracic.  
FEV1 %              =   observed FEV1 / predicted  FEV1  <  80% 
 
FEV1 / FVC %   =   observed FEV1 /  observed  FVC  <  75% 
 
Severity  of obstruction can be graded based on FEV1%  based on 
GOLD criteria as 80% mild, 80%-50% moderate,50%-30% severe,<30% 
very severe 
 
  FEV1 /FVC may erroneously be normal due to air trapping which 
cause markedly  
 
Reduced FVC in  persons with moderate to severe obstruction. 
 
  FEV1 / FVC will be less than 70-80% in elderly due to age related 
decline without major obstruction. Early   stages of neuromuscular 
disorders  can cause  low  
 
FEV1 /FVC  due to  reduction in FEV1. In obstructive disorders   
MMFR, PEFR are reduced to less than 75% of their predicted values . 
 
 
 
       
CLASSIFICATION BASED ON FEV1 AND FVC VALUES 
       
 
 
RESTRICTIVE PATTERN: 
Pleural and parenchymal fibrotic diseases, chest wall 
diseases 
 
FVC %  =  observed FVC / predicted FVC  <  75% 
 
Reduced FVC is not sufficient for diagnosis but it can suggest the 
probability of  restrictive  abnormality. It mainly depends on patient’s  
performance .  fallaciously low values of  FVC occurs in moderate to 
 
 
severe obstruction . Restrictive  diseases has to be confirmed by extent  of  
Residual  volume (RV) and Total Lung Capacity (TLC) by Helium 
dilution technique and Body Plethysmography. However interpretation of 
spirometric data with clinical correlation is sufficient for all practical 
purposes. 
      
  
 
 
 
INTERPRETATION OF SPIROGRAM 
     
 
 
 
 
 
 
The spirometric proportions are recorded in a graphic representation 
called Flow –Volume loop. It has volume in X axis and  time in Y axis. At 
point zero both flow and time are zero. Once the patient exhales it reaches 
a crest within 150ms which is called Peak Expiratory Flow( PEF). This 
peak flow represents the air exhaled from the proximal larger airways. 
After the peak the curve rapidly descends and reaches 25% , which is 
called FEF 25%.  
 
       
 
 
After 75% of the air exhaled it reaches FEF 75%.  
The mean flow between 25% and 75%  is called FEF 25-75% . This 
gives a measure of airflow in the medium sized airways. This parameter 
is the first to decline in most of the respiratory diseases.  Almost 90% of 
the air is exhaled in the first second . FVC is achieved if the flow 
reaches zero. 
 
Obstructive Airway  Disease:  
In  obstructive  airway diseases like COPD and Asthma the small 
airways are narrowed and flow volume loop shows a concave pattern or 
scooped out pattern.  
 
 
 
 
 
The  PEF  is normal since the air in larger airways is expelled easily. 
Since smaller airways are narrowed the air is expelled slowly leading to a 
low flow. This causes sharp fall in the flow volume loop. Both FEV1 and 
FEF 25-75 are low. 
      
Obstructive airway disease: 
 
Fig: low FEV1 
 
 
 
 
 
 
 
Restrictive Lung Disease:  
 
       Restrictive lung diseases are characterized by low total lung volume .  
spirometry can point out the probability of restriction and it has to be 
established by other methods. Since there is no obstruction the curve of 
flow volume is normal but the FVC is reduced. Peak Expiratory Flow can 
be normal or low. 
 
       Fig: Low FVC with normal shape in restrictive lung disease:  
 
  
 
 
 
 
 
 Fig: Too low  FEV1 in restrictive lung disease in volume - time curve. 
 
UPPER AIRWAY OBSTRUCTION (UAO) : 
 
The following are the characteristics of upper airway obstruction.  
 
 Midpoint maximal inspiratory flow is FIF 50% < 100 L/min  
 Ratio of midpoint maximal expiratory flow to midpoint maximal 
inspiratory flow: FEF50% > 1/FIF50%  
 Ratio of forced expiratory volume in 1 second to peak expiratory 
flow rate  FEV1/PEFR > 10 ml /L/minute  
 
 
 
 Ratio of forced expiratory volume in 1 second to forced expiratory     
volume in 0.5  seconds FEV1/FEV0.5 > 1.5  
 
Extra thoracic obstruction  can  be classified into following categories. 
 
1. Extra thoracic  Obstruction 
-variable 
The obstruction is more significant during inspiration and expiration 
is normal. This occurs due to the fact that during expiration the obstruction 
is overcome by the force of expiration. In flow –volume loop the 
inspiratory part is flattened and expiratory part is normal.  
e.g :laryngeal tumours, extrathoracic goiter, paralysis of vocal cord.  
 
 
    
   
 
 
2. Intra thoracic Obstruction - 
variable  
In intra thoracic obstruction, during inspiration the trachea is 
sucked out and during expiration it causes partial obstruction. 
Inspiratory part of the flow – volume loop is normal and the expiratory 
part is flattened.  
 
 
2. Fixed obstruction of the  Large 
Airways:  
 
The obstruction can be both extra thoracic and intra thoracic. Both  
inspiratory and expiratory part of the flow- volume loop are flattened.  
e.g.   intra tracheal tumours, tracheal stenosis.
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TROUBLESHOOTING: Common cause for inconsistent spirometry is 
patient technique. Other causes are as follows   
1. Incomplete inspiration and sub optimal expiration 
2. Delayed maximal effort that under estimates FEV1      
3. Inadequate emptying of lungs occurs commonly in COPD 
4. Incomplete sealing of lips around mouth piece underestimates FVC 
and FEV1 
5. Exhalation through nose 
6. Coughing  
7. Mouth piece obstruction by teeth  
. 
 
 
 
    
. 
 
 
AIMS AND OBJECTIVE 
  
 
 
 
AIMS AND OBJECTIVE 
 
1. Early detection of COPD in asymptomatic smokers by using 
spirometer in south India. 
2. To correlate BMI, smoking index and age of onset of first smoke 
with FEVI/FVC Ratio. 
3. To Study the relationship between SI and FEV1FVC ratio with 
severity of COPD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND 
METHODS 
  
 
 
MATERIALS AND METHODS 
 
PLACE OF STUDY:  
MAHATMA GANDHI MEMORIAL GOVERNMENT 
HOSPITAL attached to KAP VISWANATHAM GOVERNMENT 
MEDICAL COLLEGE, TIRUCHIRAPPALLI in southern region of 
India 
 
DEPARTMENT IN WHICH STUDY CONDUCTED:  
Department of General Medicine 
 
PERIOD OF STUDY: From    JANUARY   2014  to  August 2014 
 
 STUDY DESIGN : A  prospective descriptive cross sectional study  
 
ETHICAL COMMITTEE: Institutional ethical committee approval 
obtained. The study population was well explained about the study and 
its purpose in local language. Informed and written consent obtained 
from study population 
 
 
 
 
 
INCLUTION CRITERIA:  
1.Subjects with history of smoking and age above 25 years 
2.No significant respiratory symptoms 
3. Regular smokers 
4. Willing to undergo spirometry 
5. Willing to give consent to participate in the study 
 
EXCLUTION CRITERIA: 
1. Subjects with smoking cessation 
2.  History of respiratory disease like tuberculosis, bronchial asthma or 
occupational lung disease  
3.  On inhaled bronchodilators or corticosteroids 
4.  Diabetes mellitus, hypertension and coronary artery heart disease 
5. Chest wall and vertebral deformities like pectus,kyphosis,scoliosis 
6. Inadequate spirometry like air escape, failure to reach plateu are 
excluded 
 
STUDY GROUP :  
Patients  attending the out patient department of tertiary care 
hospital ,MAHATMA GANDHI MEMORIAL GOVERNMENT 
HOSPITAL attached to KAP VISWANATHAM GOVERNMENT 
MEDICAL COLLEGE, TIRUCHIRAPPALLI in southern region of 
India 
 
 
SAMPLE SIZE: Calculated from prevalence in North Indian and 
Madras study. Total number of subjects included was 174. All are men 
with history of smoking 
 
MATERIALS:  
1.EASY ONE spirometer 
2. Disposable mouth piece 
3. Weighing scale 
4. Stadiometer 
5. Printed materials explaining ill effects of smoking and benefits of 
smoking cessation regarding health and financial concerns 
 
SPIROMETER 
 Easy one  spirometer. It is a handy spirometer based on ultra sonic flow 
sensor system. The benefit of this spirometer is disposable flow tube can 
be inserted between transducers that prevents cross infectivity. in view of 
the fact that the tube acts a transparent barrier sorting out the airflow and 
transducer it does not require calibration. Also  this spirometer is not 
affected by the composition of gas is added advantage. This type of 
compact, microprocessor integrated spirometer is recommended in various 
studies for screening of smokers for COPD. In our study we used same 
type of instrument which can be connected to computer to get the report. 
 
 
 
 
 
 
 
METHODOLOGY 
After getting consent from subjects they were given short lecture 
using printed modules in a language Tamil and demonstration of 
spirometry is done by the technician who does the procedure. Quantum 
of smoking was calculated using smoking index. 
Smoking index: number of cigarettes or bidies per day mutiplied by 
number of years of smoking. Smoking index selected because number of 
cigarettes,bidis vary depending upon the manufacturer hence it is more 
 
 
appropriate than pack years. 
 
Height ,weight and BMI was considered.  They were subjected to 
spirometry 15 mins after 400 mcg of salbutamol  nebulisation as per 
GOLD criteria. The predicted and measured values of FEV1, FVC, 
FEV1/FVC, PEFR,FEF 25-75  for all the patients were recorded. 
Minimum of three trials and maximum of eight trials done for each 
subject based on guidelines from American Thoracic Society. 
 
  The  data were analyzed as per GOLD criteria and the subjects 
classified as mild, moderate, severe and very severe air flow obstruction 
using statistical test. 
 
 
 
 
 
      
 
 
 
RESULTS 
   FIGURE - 1  Age   distribution  of smokers in percentage 
 
 
28-38 years 28.7% (n=50) 
39-49 years 38.5% (n=68) 
50-60 years 29.3% (n=51) 
61-71years   2.8%    (n=5) 
  
PERCENTAGE OF SMOKERS 
 28-38 YEARS 
39-49 YEARS 
50-60 YEARS 
61-71 YEARS 
 
 
                      FIGURE - 2  BMI distribution of smokers in percentage 
 
BMI – Body mass index 
1. <18.5               5.17% (n=9) 
2.   18.5- 24.9      76.43% (n=134) 
3.  25.0- 29.9        13.21%(n=23) 
4.   30.0-34.9        4.02% (n=8) 
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FIGURE - 3 Smoking index distribution in smokers 
 
SI 
NUMBER OF 
SMOKERS 
PERCENTAGE 
<100 7 4.02% 
101-299 133 76.43% 
>300 34 19.43% 
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FIGURE - 4 Age of  first smoke among smokers 
 
 
1. Youngest age is 16 years 
2. Maximum number observed is at 18 years 
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FIGURE- 5  Distribution of obstructive lung disease in spirometry 
 
 
Normal spirometry – 82.18%(n=143) 
Obstruction              - 17.81%(n=31) 
Among  obstructive pattern 
Mild  obstruction    - 61.29%(n=19) 
Moderate obstruction- 38.7%(n=12) 
 
PERCENTAGE OF OBSTRUCTION 
NORMAL 
OBSTRUCTION 
 
 
TABLE 1 
PARAMETERS 
(N=174) 
MEAN(SD) MINIMUM MAXIMUM 
AGE 44.9943 (8.794) 28 65 
ONSET 
20.65      
(2.634) 16 26 
BMI 22.6925 (3.101) 16.5 32 
SI 
226.821 
(77.315) 80 450 
FVCp 
87.31      
(58.383) 58 822 
FEV1p 
79.97      
(16.248) 51 152 
FEV1/FVCp 
98.55      
(17.961) 60 139 
MEF 25-75 
64.4        
(31.458) 11 191 
MEF 75 
68.68      
(23.448) 18 137 
MEF 50 
66.66      
(24.668) 22 133 
MEF 25 
59.90      
(32.588) 7 247 
PEF 
69.74      
(22.198) 24 128 
FVC m 
3.2059    
(.78459) 1.33 5.46 
FEV1m 
2.7059    
(.68959) 1 4.53 
FEV1/FVC m 
.7755      
(.07193) 0.18 0.85 
 
 
 
 
Onset    - age of first smoke 
BMI      -Body mass index 
SI          -Smoking index 
FVCp   - Forced vital capacity (Percent) 
FEV1p – Forced expiratory volume in 1 second( percent) 
MEF 25-75 – Mid expiratory flow  
PEF   - Peak expiratory flow 
FVCm   - Forced vital capacity (measured) 
FEV1m – Forced expiratory volume in 1 second(measured) 
                                       
  
 
 
TABLE 2 
 ONE SAMPLE T TEST 
PARAMETERS 
(N=174) 
MEAN(SD) p VALUE 
AGE 44.9943 (8.794) 0.075 
ONSET 20.65      (2.634) 0.001*** 
BMI 22.6925 (3.101) 0.101 
SI 226.821 (77.315) 0.001*** 
FVCp 87.31      (58.383) 0.001*** 
FEV1p 79.97      (16.248) 0.002** 
FEV1/FVCp 98.55      (17.961) 0.018* 
MEF 25-75 64.4        (31.458) 0.065 
MEF 75 68.68      (23.448) 0.651 
MEF 50 66.66      (24.668) 0.062 
MEF 25 59.90      (32.588) 0.035* 
PEF 69.74      (22.198) 0.564 
FVC m 3.2059    (.78459) 0.054 
FEV1m 2.7059    (.68959) 0.322 
FEV1/FVC m .7755      (.07193) 0.001*** 
 
*is p value <0.05 
**is p value <0.01 
***is p value < 0.001 
 
 
TABLE 3A 
 
ONSET FVCm FVCp FEV1m FEV1p FEV1FVCm FEV1FVCp 
CHI 
SQUARE 64.613a 107.609b 77.59c 87.33b 180.39d 108.46e 79.36d 
Df 10 97 52 97 46 21 46 
p 
VALUE 0.001*** 0.217 0.012* 0.749 0.001*** 0.001*** 0.002** 
         
TABLE 3B 
 
PEF 
MEF25-
75 MEF75 MEF50 MEF25 BMI SI AGE 
CHI 
SQUARE 69.86f 61.55g 71.07h 85.03i 98.41j 108.89k 240.25l 57.72m 
Df 67 80 68 71 78 83 39 35 
p VALUE 0.382 0.938 0.376 0.122 0.059 0.03* .001*** .009** 
 
*is p value <0.05 
**is p value <0.01 
***is p value < 0.001 
 
 
TABLE 4 
 
HEIGHT WEIGHT ONSET FVCm FVCp FEV1m FEV1p FEV1FVCm FEV1FVCp PEF 
MEF25-
75 BMI SI AGE 
HEIGHT 1 
             p VALUE 
              WEIGHT .391*** 1 
            p VALUE 0.001 
             ONSET -0.013 -0.046 1 
           p VALUE 0.862 0.546 
            FVCm .482*** .192* -0.034 1 
          p VALUE 0.001 0.011 0.661 
           FVCp -0.057 -0.032 0.123 -0.034 1 
         p VALUE -0.034 0.672 0.106 0.658 
          FEV1m .460*** .243*** -0.085 .956*** -0.042 1 
        p VALUE 0.001 0.001 0.268 0.001 0.586 
         FEV1p 0.014 0.044 0.069 0.002 0.049 0.007 1 
       
 
 
p VALUE 0.859 0.567 0.369 0.979 0.521 0.923 
        FEV1FVCm 0.044 0.063 0.021 0.084 -0.125 0.126 .257*** 1 
      p VALUE 0.565 0.406 0.78 0.272 0.099 0.098 0.001 
       
FEV1FVCp -0.077 -0.021 -0.042 -0.088 
-
.229** -0.088 .254*** .460*** 1 
     p VALUE 0.312 0.787 0.583 0.25 0.002 0.25 0.001 0.001 
      PEF 0.128 .193* 0.008 .154* -0.135 .167* .377*** .345*** .353*** 1 
    p VALUE 0.092 0.011 0.916 0.043 0.075 0.028 0.001 0.001 0.001 
     MEF25-75 0.078 -0.004 0.018 0.091 -.151* 0.089 .383*** .313*** .704*** .485*** 1 
   p VALUE 0.307 0.961 0.81 0.234 0.046 0.241 0.001 0.001 0.001 0.001 
    BMI -.259*** .756*** -0.037 -0.106 0.003 -0.039 0.05 0.038 0.039 .167* -0.047 1 
  p VALUE 0.001 0.001 0.633 0.163 0.973 0.606 0.511 0.616 0.606 0.028 0.535 
   
SI -0.006 -0.036 -0.009 -.187* 0.133 -.225** -.158* -.476*** -.406*** 
-
.256*** -.216** 
-
0.041 1 
 
p VALUE 0.94 0.636 0.902 0.014 0.08 0.003 0.038 0.001 0.001 0.001 0.004 
 
0.593 
  
 
 
 
AGE -.197** -0.13 0.069 -.387** 0.114 
-
.478*** -0.058 -.300*** -0.04 -0.088 -0.046 0.017 .616*** 1 
Pvalue 0.009 0.088 0.364 0.003 0.135 0.001 0.445 0.001 0.6 0.247 0.543 0.82 0.001 
  
 
*is p value <0.05 
**is p value <0.01 
***is p value < 0.001 
 
 
 
 
 
 
 
Summary 
  
 
 
                                           SUMMARY 
FIGURE 1  Shows 
 Age   distribution of smokers in percentage 
39-49 years 38.5% (n=68) is commonly observed data 
FIGURE 2 shows 
BMI distribution of smokers in percentage 
   18.5- 24.9      76.43% (n=134)    
 FIGURE 3 shows 
Smoking index distribution in smokers 
SI 101-299  in 76.43% (n=133) 
FIGURE 4  shows 
Age of  first smoke among smokers 
1. Youngest age is 16 years 
2. Maximum number observed is at 18 years 
 FIGURE 5  shows  
 Distribution of obstructive lung disease in spirometry 
Normal spirometry – 82.18% (n=143) 
 
 
Obstruction              - 17.81%(n=31) 
Among  obstructive pattern 
Mild  obstruction    - 61.29% (n=19) 
Moderate obstruction- 38.7% (n=12) 
TABLE 1 
Distribution of parameters in mean and standard deviation 
Age group – 44.99(8.79) in years 
Age of first smoke  - 20.65 (2.634) in years 
BMI – 22.69(3.10) 
SI  -  226.82 (77.31) 
FVCp – 87.31( 58.38) 
FEV1p -79.97(16.24) 
FEV1FVCp – 98.55(17.96) 
MEF 2575 – 64.4(31.45) 
MEF75 – 68.68 (23.44) 
MEF50 – 66.66(24.66) 
MEF25- 59.9(32.58) 
 
 
FEV1m – 2.70(.071) 
FEV1FVCm - 0.77(0.071) 
FVCm – 3.2 (0.78) 
 
TABLE 2 
One sample T test 
FEV1FVCp    and  MEF25 have   p value  < 0.05   
FEV1p has p value <0.01 
Age of first smoke, SI,FVCp and FEV1FVCm have p value <0.001 
 
TABLE 3 
Chi square test  
 BMI - 108.46 (p value  <0.05 )and FVCp -77.59(p value  <0.05) 
 Age - 57.724(p value < 0.01 ) and FEV1FVCp -79.386(p value 
0.002) 
Age of first smoke , SI -240.25, FEV1p- 180.39  and  FEV1FVCm 
-108.46  
   p value < 0.001 
 
 
TABLE 4 
Correlation coefficient 
SI has significant negative correlation with FEV1m  _ 
0.225(p 0.003) ,FEV1p _0.158 ( p 0.03), FEV1FVCm 
_0.476(p0.001) , FEV1FVCp _0.406 ( p 0.001) , PEF _0.256 (p 
0.001) ,MEF 25-75 _0.216(P 0.004) 
FEV1FVCm   has significant positive correlation with 
FEV1p 0.257 (p 0.001) 
FEV1FVCp  has significant negative correlation with  
_0.229 (p 0.002)  and significant positive correlation with FEV1p 
0.254 (p 0.001), FEV1FVCm 0.460 ( p0.001) 
MEF 25-75 has significant positive correlation with FEV1p 
0.383(p 0.001) , FEV1FVCm  0.313 (0.001) ,  FEV1FVCp  0.704 
(p 0.001) ,PEF 0.485 ( p 0.001) 
  
 
    
 
 
 
 
 
 
 
DISCUSSION 
  
 
 
DISCUSSION 
This study was conducted for earlier detection of  COPD in 
smokers even before the occurance of symptoms and signs of obstructive 
lung disease. The diagnostic criteria used for case finding is as specified 
in GOLD guidelines. The portable spirometer (Easy one)was used to 
perform the spirometry. The population in the study group is 
representative of patients attending the out patient department in the 
tertiary care hospital Tiruchirappalli,South India. The prevalence of 
COPD in this population is 10.2%. the prevalence of smoking has 
increased and 50% of male smoke cigarette or bidis. Our  aim is to detect 
the presence of COPD earlier in asymptomatic smokers and to correlate 
the severity of obstructive pattern with SI. 
All the participants were male. Since female smoking is not 
socially accepted in this region only a little proportion smoke. It was 
ensured that all the participants continue to smoke and does not have 
respiratory symptoms and signs during the study. Occupational history 
suggestive of exposure to lung disease have been excluded from the 
study. Most of them were sales representatives, vendors and auto/taxi 
drivers.  
All are subjected to 400 mcg salbutamol nebulisation fifteen 
minutes prior to spirometry as per GOLD guidelines. Spirometry was 
 
 
performed by single technician by demonstrating technique before study. 
Participants were well informed with printed material regarding ill effects 
of smoking and benefits of smoking cessation. 
The parameters collected were  age of first cigarette, 
BMI,SI,FEV1,FEV1/FVC both measured and percent,MEF25-
75,MEF75,MEF50 and MEF 25. The results were statiscally  analyzed.  
AGE: The mean age was 44.994 (8.794). Most of them were 
between 39-49 years(n=67) 38.5%. youngest age in this study is 28 years. 
Age group 61-71 years is only 2.87% (n=5). significant negative 
correlation with FVCm _0.387(p 0.003), FEV1m _0.478(p 0.001) 
,FEV1FVCm _0.300(p 0.001).This correlates well with Natural history 
pattern of COPD in which as the  age advances the severity of disease 
progresses as explained by Fletcher and Peto curve. Less number of 
patients in >60 years is probably due to occurrence  of symptoms as age 
advances and Our study included only asymptomatic patients.  
BMI:  The mean BMI was 22.6925(3.1010). about 76.43(n=133) 
were in 18.5-24.9 BMI range. Underweight noted only in 5.172%(n=9) 
probably our study included only asymptomatic population of smokers. 
Since most of the participants are middle aged working group they were 
in BMI range of normal to overweight 89.64% (n=140). There is no 
correlation of BMI with severity of obstructive pattern in our study. 
 
 
SMOKING INDEX: About 78.735% (n=137) participants had 
moderate SI i.e 100-300. Severe SI observed in 21.26%(n=37). SI and 
age has significant positive correlation coefficient 0.616(p 0.001) which 
is consistent with previous studies. SI and FEV1/FVC ratio both m and p 
has significant negative correlation coefficient (p 0.001) i.e SI increases 
FEV1/FVC ratio decreases. Moderate obstruction had SI of  400 (88.25) 
and mild obstruction had SI of 310(66.50). SI also has significant 
negative  correlation coefficient (p 0.001) with MEF 25-75 which is again 
consistent with presence of  small airway disease in smokers with COPD. 
This parameter was  less correlated in previous  north Indian study . 
FEV1m_ 0.225(p 0.003) , FVCm _0.187(0.01) alone had correlation with 
SI for diagnosis  of obstructive lung disease. When percentage is 
considered they does not correlate. Thus FEV1/FVC ratio is gold 
standard for screening presence of airflow limitation in smokers as 
indicated in study   Stralelis G, et al  and Zielinski et al. is consistent with 
our study. 
 Age of first smoke: Majority started smoking around 20 years. 
About 1/5 th (n=37) 19.54 % started to smoke at 18 years. Age of first 
smoke does not have any correlation with obstructive lung disease in our 
study(p=.839). It is the quantity of smoke and not the duration of smoke 
 
 
correlates with severity of airflow limitation. Previous  studies also given 
the same report. 
FVC: It has also got significant negative correlation coefficient  (p 
0.001) with FEV1/FVC ratio. These are well established in various 
studies and reproduced in our study also. 
 FEV1: Significant positive correlation coefficient (p 0.001) 
with,FEV1/FVC, MEF 25-75 which is consistent from previous studies. 
According to GOLD criteria 19/174 had mild and 12/174 had moderate 
obstruction pattern. All the participants with obstructive spirometry are 
asymptomatic during study. But when only FEV1 value is considered 
57.47% (n=100) had FEV1 >80. 42.52% (n=74)had FEV1 50-80%. So in 
determining the obstructive pathology we need FEV1/FVC or 
FEV1/FEV6. FEV1 alone is not useful as screening criteria for diagnosis 
of COPD in asymptomatic smokers. 
 FEV1/FVC: Airflow limitation with FEV1/FVC ratio <70 was 
noted in 17.816%(n=31). Out of which when applied to GOLD guidelines 
mild obstruction noted in 61.2903%(n=19). Moderate  obstruction seen in 
38.7096%(n=12). None of them had severe or very severe obstruction. 
FEV1/FVC has Significant positive correlation coefficient (p 0.001) with 
FEV1and MEF25-75 . It has also got significant negative correlation 
coefficient (p 0.001) with SI and FVC. 
 
 
 MEF25-75: has Significant positive correlation coefficient (p 
0.001) with FEV1p and FEV1/FVCm ,  FEV1FVCp   ratio . It has also 
got significant negative correlation coefficient (p 0.001) with SI. This 
parameter is less correlated in previous trials used for screening of 
COPD. This parameter needs further large trials. 
 
 
 
 
 
 
 
 
 
 
                                          
 
 
 
 
 
 
 
 
 
CONCLUSION 
  
 
 
CONCLUSION 
1. The most common age of first smoking is 18 years and all 
participants had started smoking by 26 years. 
2. The youngest age of first smoking is at 16 years  
3. The age of first smoking does not have significance with airflow 
limitation 
4. The most common age group found is 39-49 years 
5. The most prevalent BMI is 18.5-24.9 and does not have 
significance in respect to airflow obstruction . 
6. SI has significant negative correlation with FEV1/FVC and 
Significant positive correlation coefficient with age. 
7. The quantum of smoking correlates with severity of airflow 
obstruction as indicated by SI 
8. There is 17.8% of asymptomatic smokers have airflow limitation in 
the form of obstructive lung disease. 
9. There is 61.29% of asymptomatic smokers had mild COPD and 
38.7% had moderate COPD as per GOLD guidelines 
10. The FEV1/FVC ratio as a screening tool to detect the  presence of 
COPD in asymptomatic smokers is established 
11. Handheld in office spirometry is useful for screening the smokers 
for presence of airflow obstruction before significant symptoms. 
 
 
12. MEF  25-75 also has significant positive correlation coefficient  
with FEV1/FVC ratio and significant negative correlation  with  SI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIMITATIONS AND RECOMMENDATIONS 
 
1. The period of study is low, large data would have been collected if 
done for long time. 
2. Serial spirometry not done on same participant since it is cross 
sectional study 
3. Study group is just adequate 
4. History regarding occupational exposure is not probed in depth 
5. Non smokers as control group not done 
6. Environmental tobacco smoking and genetic predisposition to COPD 
are not ruled out. 
7. Economic burden  of individual due to smoking is not calculated 
8. MEF 25-75 value needs further large trials to use as earlier tool for 
airflow limitation 
9. Regular use of hand held spirometer by primary care physician is 
recommended to screen airflow limitation in asymptomatic smokers 
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MASTER CHART 
S.NO. AGE HEIGHT WEIGHT BMI ONSET PY SI FVCm FVCp FEV1m FEV1p FEV1/FVCm FEV1/FVCp PEF 
MEF25-
75 MEF75 MEF50 MEF25 
1 32 170 60 20.8 20 12 240 3.36 126 3.02 78 0.6 60 41 43 34 40 83 
2 53 171 56 19.2 23 9 180 3.67 76 2.98 84 0.78 116 91 114 100 133 123 
3 43 146 45 21.1 23 10 200 2.46 70 2.09 54 0.66 66 54 18 43 22 12 
4 36 160 58 22.7 23 8 160 2.72 58 1.98 79 0.72 139 80 113 81 78 247 
5 44 160 60 23.4 20 10 200 3.11 69 2.7 78 0.84 116 53 76 56 79 109 
6 60 172 65 22 24 36 720 3.85 35 2.99 78 0.53 72 21 7 7 6 9 
7 33 175 58 18.9 20 6 120 5.09 69 4.31 82 0.83 121 68 86 75 83 111 
8 43 160 62 24.2 21 12.5 230 3.33 75 2.9 79 0.84 109 60 69 63 70 78 
9 39 165 45 16.5 20 8 160 2.52 73 2.15 69 0.82 99 73 50 74 80 84 
10 54 148 55 25.1 16 7.2 144 2.78 70 2.31 58 0.77 89 49 25 44 31 24 
11 50 160 50 19.5 18 7.5 150 3.58 106 2.94 100 0.78 99 37 18 18 24 35 
12 44 165 55 27.1 19 10 200 4.02 82 3.33 80 0.79 101 112 57 84 61 59 
13 43 160 55 25.4 24 11.5 230 3.11 76 2.7 78 0.84 106 102 73 83 79 67 
14 38 154 60 25.3 20 5 102 3.28 83 2.86 72 0.84 89 64 41 66 46 35 
15 41 159 57 22.5 21 11.5 230 3.5 86 3.05 63 0.69 69 38 33 42 33 27 
16 59 160 63 24.6 18 20 400 3.44 55 2.99 65 0.67 67 31 9 28 16 5 
17 53 175 65 21.2 19 9 180 4.36 89 3.5 93 0.78 107 65 90 73 86 110 
18 50 148 50 26.5 23 5 100 2.88 74 2.42 86 0.78 125 68 82 74 85 137 
19 42 158 60 22 25 10 200 2.57 87 2.2 73 0.81 89 76 33 61 39 26 
20 65 148 45 20.5 22 20 400 1.99 69 1.62 84 0.77 130 72 99 70 98 128 
21 43 160 57 22.3 25 11.5 230 3.65 95 3.23 79 0.83 89 71 44 58 52 51 
22 33 157 55 21.5 20 4.8 96 2.97 78 2.58 68 0.84 90 38 41 37 47 27 
23 45 160 52 20.3 17 13 260 1.58 155 1.25 152 0.75 104 25 21 19 81 122 
24 50 163 54 20.3 19 18 320 3.65 74 3.19 51 0.69 69 36 27 33 29 89 
25 34 158 54 21.6 18 8.5 170 3.02 83 2.62 83 0.84 103 83 75 88 86 60 
 
 
26 38 150 70 31.1 17 10 200 2.66 69 2.77 81 0.81 122 109 106 110 107 144 
27 38 168 64 22.7 18 15 315 4.35 76 3.63 54 0.68 68 40 24 34 37 29 
28 33 160 59 23 17 17 340 2.9 71 2.5 60 0.68 68 26 30 38 35 23 
29 39 168 69 24.4 16 10 200 3.61 82 3.89 82 0.82 104 82 81 91 90 72 
30 58 154 56 23.6 19 15.5 330 3.02 69 2.45 67 0.77 102 47 48 47 49 54 
31 44 173 58 19.4 25 13.5 270 4.48 65 3.67 84 0.7 70 32 37 34 38 36 
32 35 186 75 21.7 17 7.5 150 5.46 87 4.49 54 0.81 99 75 78 85 89 57 
33 41 171 61 20.9 20 10 200 4.44 73 3.67 81 0.7 70 76 23 47 29 39 
34 53 156 60 24.7 21 15 300 3.27 73 2.68 71 0.78 69 93 55 96 81 37 
35 31 169 69 24.2 23 13 260 4.74 81 4.05 75 0.83 95 67 58 82 75 46 
36 51 151 60 26.3 18 15 300 2.47 103 2.09 80 0.69 70 52 62 75 85 40 
37 51 150 50 22.2 21 10 200 2.97 67 2.48 60 0.79 96 61 34 46 60 40 
38 56 155 55 22.9 25 17.5 350 3.13 80 2.55 98 0.77 130 52 112 52 97 77 
39 56 160 56 21.9 21 15 300 3.42 89 2.77 83 0.77 112 54 191 59 93 110 
40 57 157 65 26.4 26 15.5 310 3.11 112 2.52 85 0.68 68 32 24 30 61 79 
41 60 160 58 22.7 25 18.5 370 2.66 64 2.13 80 0.7 70 63 49 53 48 48 
42 53 170 65 22.5 23 17.5 350 2.38 100 2 80 0.69 69 61 23 48 48 150 
43 37 156 51 21 18 10 200 3.68 101 3.14 91 0.81 96 46 68 45 79 61 
44 44 160 82 32 17 10 200 3.73 84 3.11 84 0.79 105 128 77 137 101 57 
45 45 168 76 26.9 24 12.5 250 3.65 70 2.85 80 0.7 70 54 25 52 48 49 
46 40 151 56 24.6 20 10 200 3.02 80 2.6 69 0.18 91 46 38 39 68 36 
47 36 158 57 22.8 20 10 200 3.82 81 3.26 75 0.81 98 66 54 68 66 45 
48 59 162 52 19.8 16 20 400 3.46 78 2.76 97 0.76 131 66 121 64 118 47 
49 53 177 60 19.2 19 15 300 4.22 98 3.29 80 0.67 67 74 27 56 31 28 
50 36 160 67 26.2 23 9 180 3.11 82 2.7 80 0.84 101 79 59 78 63 51 
51 39 163 64 24.1 18 10 200 2.87 79 2.47 79 0.81 106 99 80 105 104 59 
52 35 174 60 19.8 19 8 160 5.03 79 4.27 81 0.83 105 68 77 72 75 76 
53 45 160 45 17.6 19 10 200 3.11 79 2.7 74 0.84 97 93 59 93 75 34 
54 60 156 54 22.2 25 17.5 350 3.09 822 2.48 52 0.65 65 24 15 22 22 12 
 
 
55 38 159 59 23.3 25 7.2 144 2.98 127 2.59 109 0.84 89 51 19 44 43 66 
56 44 161 60 23.1 20 11 220 3.79 112 3.76 109 0.79 102 72 88 82 108 89 
57 46 151 68 29.8 22 13.5 270 2.43 130 2.04 109 0.85 83 85 61 84 74 39 
58 47 160 79 30.9 19 13.5 270 2.53 77 2.15 88 0.8 121 49 33 70 60 77 
59 35 170 75 26 20 18 360 4.82 90 4.03 80 0.69 69 48 33 47 37 33 
60 60 160 55 21.5 17 17.5 350 2.69 62 2.16 78 0.76 132 107 158 109 60 62 
61 45 150 54 24 25 12 240 2.36 80 2 81 0.68 68 55 11 42 23 70 
62 57 160 45 17.6 21 17.5 350 3.39 80 2.27 70 0.77 91 51 33 56 51 22 
63 42 171 63 21.5 22 18 360 2.15 81 1.8 80 0.7 70 44 54 42 32 21 
64 36 172 65 22 18 6 160 3.3 67 2.92 80 0.74 123 83 121 89 102 45 
65 63 175 65 21.5 20 11.4 228 3.84 67 2.92 80 0.74 102 78 101 81 76 51 
66 39 162 58 22.1 25 10 200 3.11 83 2.7 95 0.84 119 76 98 75 96 46 
67 61 171 69 23.6 19 20 400 3.05 95 2.59 84 0.77 97 104 56 85 77 29 
68 44 159 57 22.5 21 11 220 4.05 84 3.54 82 0.83 103 88 73 97 82 72 
69 49 160 56 21.9 22 15 300 2.82 116 2.1 80 0.69 69 54 56 78 70 59 
70 39 169 65 22.8 17 15 300 3.95 114 3.45 81 0.69 69 57 61 60 41 39 
71 60 140 58 29.6 19 10.5 210 2.26 64 2.13 65 0.76 105 63 49 63 60 58 
72 36 175 68 22.2 25 9 180 4.59 75 3.79 77 0.85 100 68 70 73 74 69 
73 47 160 62 24.2 18 10 200 3.54 59 2.94 57 0.79 103 47 44 46 49 50 
74 44 170 82 28.4 22 11 220 3.73 84 3.11 85 0.79 105 128 77 137 101 57 
75 49 166 52 17.9 22 10 200 3.46 78 2.76 97 0.76 131 66 131 64 117 77 
76 44 168 60 21.3 24 8.8 176 3.4 70 2.83 63 0.85 83 68 26 73 46 9 
77 63 177 65 20.7 22 20 400 4.22 81 3.69 80 0.66 66 74 57 54 23 7 
78 44 170 67 23.2 23 11 220 3.11 82 2.7 80 0.84 101 79 59 78 63 51 
79 39 163 64 24.1 22 9.5 190 2.87 78 2.47 79 0.82 106 99 80 105 104 59 
80 35 174 60 19.8 20 8.5 170 5.03 79 4.27 81 0.8 105 68 77 72 75 76 
81 35 160 60 23.4 18 8.5 170 3.11 79 2.6 75 0.84 97 93 59 93 75 34 
82 40 166 58 21 18 9.5 190 3.68 66 3.21 61 0.83 97 57 45 65 46 42 
83 58 160 60 23.4 21 22.5 450 3.09 82 2.48 51 0.65 65 24 15 22 26 12 
 
 
84 46 163 63 23.7 18 8.8 176 3.79 112 3.16 109 0.79 102 72 88 82 108 89 
85 36 161 70 27 24 9 180 2.43 130 2.04 109 0.85 83 85 61 84 74 39 
86 47 162 70 26.7 18 11 220 2.53 77 2.15 88 0.8 121 49 52 42 60 77 
87 52 160 55 21.5 25 8.1 162 2.69 62 2.16 78 0.76 110 107 150 100 60 46 
88 49 160 56 21.9 25 12 240 3.11 83 2.7 95 0.84 119 70 98 75 96 146 
89 51 173 60 20 19 15 300 3.05 95 2.59 84 0.77 97 104 56 85 76 39 
90 38 157 56 22.7 21 10 200 4.05 85 3.5 83 0.83 103 88 73 97 82 72 
91 49 160 58 22.7 18 10 200 2 68 1.65 70 0.79 110 35 45 49 42 74 
92 48 165 62 22.8 24 7.2 144 4.22 88 3.66 86 0.83 115 65 89 71 94 128 
93 48 168 65 23 24 11.2 224 2.84 64 2.42 75 0.8 125 68 85 75 80 66 
94 52 155 56 23.3 20 13.5 270 1.66 65 1.33 68 0.75 94 43 53 39 33 25 
95 61 159 50 21.8 25 20 400 2.97 110 2.29 80 0.69 69 99 39 74 43 26 
96 49 166 60 21.8 21 12 240 1.79 95 1.44 100 0.76 112 83 62 73 51 84 
97 30 170 68 23.5 19 5 100 3.3 95 2.9 77 0.8 84 87 12 70 59 95 
98 49 170 62 21.5 20 10 200 2.17 81 1.8 69 0.77 91 76 28 67 36 21 
99 39 166 60 21.8 24 9.5 190 4.2 90 3.5 78 0.8 88 113 41 78 50 33 
100 55 160 75 29.3 20 12 240 2.55 74 2.15 71 0.79 103 62 59 68 77 36 
101 39 169 69 24.2 25 9.5 190 2.96 74 2.55 78 0.82 110 38 70 28 46 67 
102 45 157 52 21.1 20 10 200 3.13 104 2.65 111 0.79 114 85 120 94 130 153 
103 51 148 68 31 20 9 180 2.74 103 2.22 116 0.76 119 120 96 127 33 56 
104 44 164 60 22.3 21 7.2 144 2.79 69 2.38 81 0.81 124 71 103 79 93 53 
105 35 160 73 28.5 20 8.5 170 2.07 89 2.65 89 0.82 104 73 81 77 86 73 
106 38 155 56 23.3 18 10 200 3.6 80 3.07 75 0.8 99 72 58 79 76 39 
107 51 153 69 28.7 18 15 300 2.56 80 2.17 75 0.79 90 59 33 60 40 24 
108 55 168 62 22 21 12 240 1.84 109 1.5 100 0.77 97 87 45 64 54 33 
109 37 162 52 19.8 25 10 200 4.03 85 3.4 73 0.81 89 60 41 58 48 36 
110 47 166 51 18.5 17 11 220 2.9 83 2.27 86 0.75 108 77 68 83 80 72 
111 59 155 65 27 25 10.2 204 2 74 1.65 74 0.79 106 44 43 47 42 51 
112 58 162 60 22.9 25 10.2 204 2.34 75 1.95 77 0.79 100 77 44 80 75 43 
 
 
113 57 160 61 23.8 24 10.2 204 2.79 66 1.45 68 0.76 118 54 64 55 71 69 
114 32 160 45 17.6 23 7.5 150 3.28 93 2.86 96 0.84 107 71 84 77 92 91 
115 57 160 59 23 17 10.2 204 2.05 71 1.7 84 0.79 125 82 90 96 93 90 
116 59 164 58 21.6 23 20 400 3.57 75 2.8 80 0.67 67 74 40 47 31 30 
117 49 163 68 25.6 19 10 200 2.57 75 2.8 68 0.76 94 74 40 57 41 40 
118 38 167 65 23.3 24 10 200 4.29 79 3.59 89 0.8 105 110 75 120 84 55 
119 43 160 58 22.7 18 9.5 190 3.11 77 2.7 68 0.84 91 48 42 38 42 53 
120 48 149 55 24.8 24 9 180 2.2 78 1.8 81 0.79 112 61 58 64 58 71 
121 37 158 50 20 18 9.5 180 2.58 114 2.21 118 0.85 105 114 120 60 74 91 
122 56 163 45 16.9 18 9 180 3.3 76 2.61 74 0.75 101 79 49 84 66 38 
123 36 171 60 20.5 26 9 180 4.29 90 3.55 97 0.85 106 100 105 95 55 60 
124 56 171 71 24.3 18 18 360 4.29 123 3.51 81 0.64 64 63 41 66 67 97 
125 39 154 70 29.5 20 9.5 190 4.05 88 3.54 96 0.83 103 99 72 99 82 71 
126 58 155 76 31.6 20 10.2 204 3.08 102 2.49 96 0.77 100 69 64 73 67 69 
127 41 162 70 26.7 24 9.5 190 2.78 75 2.38 79 0.81 112 89 92 94 74 67 
128 37 160 61 23.9 22 9.5 180 3.05 92 2.65 74 0.84 84 47 62 68 71 47 
129 50 161 62 23.9 18 15 300 2.45 101 2.08 102 0.8 108 71 93 73 97 94 
130 28 163 45 16.9 20 5 100 4.4 73 3.79 82 0.83 118 90 96 102 87 40 
131 43 159 63 24.9 18 9.5 190 3.04 89 2.61 80 0.81 96 75 51 81 49 57 
132 50 155 50 19.8 24 15.5 310 2.77 96 2.14 81 0.69 69 54 46 36 34 42 
133 52 155 50 19.8 19 14 280 2.72 62 2.09 61 0.74 102 52 38 57 46 39 
134 29 169 58 20.3 24 5 100 3.64 74 3.17 88 0.84 115 72 101 79 85 43 
135 28 160 48 18.7 19 4 80 3.55 86 3.1 89 0.84 107 62 87 67 88 60 
136 43 167 63 22.6 20 9.5 190 4.16 63 3.44 84 0.79 94 52 60 59 75 39 
137 56 160 50 19.5 24 10.2 204 2.84 83 2.34 78 0.77 99 90 46 60 53 48 
138 53 158 45 18 22 9 180 1.33 103 1 83 0.74 84 34 31 25 32 52 
139 49 160 50 19.5 23 12 240 3.6 82 2.97 75 0.79 96 78 45 83 74 31 
140 37 160 50 19.5 19 9.5 180 2.68 95 2.29 100 0.85 106 88 105 100 112 87 
141 32 180 88 27.8 18 6 120 5.38 89 4.53 80 0.83 91 85 57 81 66 42 
 
 
142 31 150 60 26.7 20 6.5 130 3.49 77 3.06 76 0.82 106 81 81 95 86 86 
143 50 155 47 19.6 18 13 260 2.68 84 2.27 84 0.8 107 88 76 95 84 63 
144 56 159 55 21.8 24 13.6 272 3.1 59 2.43 75 0.75 133 53 89 73 63 68 
145 33 155 64 23.5 22 7 140 3.73 76 3.22 75 0.81 105 68 77 75 113 62 
146 50 162 60 22.9 19 9 180 3.17 58 2.45 69 0.75 122 86 108 93 89 65 
147 36 166 64 21.9 20 9 180 3.39 58 2.74 71 0.77 130 71 81 79 70 37 
148 58 159 50 19.8 18 20 400 3.05 68 2.38 54 0.69 69 51 19 36 24 22 
149 39 170 65 22.5 18 20 400 3.29 70 3.83 55 0.68 68 41 26 38 31 26 
150 47 165 55 20.2 19 22.5 450 2.79 70 2.38 50 0.68 68 26 24 21 26 33 
151 46 165 55 20.2 17 11 220 2.79 63 2.37 74 0.8 125 69 83 70 83 90 
152 31 160 50 19.5 24 6.5 130 3.37 91 2.9 82 0.84 107 65 78 67 82 78 
153 37 165 60 22 18 9.5 180 2.43 130 2.04 109 0.85 83 85 61 84 74 39 
154 48 166 67 24.3 18 13 260 2.53 77 2.15 88 0.8 121 49 52 42 60 77 
155 51 170 71 24.6 22 15 300 2.69 62 2.16 78 0.76 110 107 150 100 60 46 
156 49 160 50 19.5 21 13 260 3.11 83 2.7 95 0.84 119 70 98 75 96 146 
157 40 168 66 23.4 23 9.5 190 3.05 95 2.59 84 0.77 97 104 56 85 76 39 
158 34 170 70 24.6 21 8 160 4.05 85 3.5 83 0.83 103 88 73 97 82 72 
159 42 170 68 23.5 18 11 220 2 68 1.65 71 0.79 110 35 45 49 42 74 
160 36 160 50 19.5 20 9 180 2.72 62 2.09 61 0.74 102 52 38 57 46 39 
161 42 165 68 25 18 9.5 190 3.64 74 3.17 88 0.84 115 72 101 79 85 43 
162 29 169 58 20.3 23 5 100 3.55 86 3.1 89 0.84 107 62 87 67 88 60 
163 28 160 48 18.7 19 5 100 4.16 63 3.44 84 0.79 94 52 60 59 75 39 
164 43 167 63 22.6 18 9.5 190 2.84 83 2.34 78 0.77 99 90 46 60 53 48 
165 56 160 50 19.5 24 18 360 1.33 103 1 83 0.74 84 34 31 25 32 52 
166 53 158 45 18 20 16.5 330 3.6 82 2.97 75 0.79 96 78 45 83 74 31 
167 49 160 50 19.5 20 9.3 186 2.68 95 2.29 100 0.85 106 88 105 100 112 87 
168 37 160 50 19.5 18 9.5 180 5.38 89 4.53 80 0.83 91 85 57 81 66 42 
169 50 155 50 20.8 18 16 320 2.77 96 2.14 81 0.69 69 54 46 36 34 42 
170 44 164 60 22.3 18 11 220 2.57 75 2.8 68 0.76 94 74 40 57 41 40 
 
 
171 35 160 73 28.5 20 8.5 170 4.29 79 3.59 89 0.8 105 110 75 120 84 55 
172 38 155 56 23.3 18 10 200 3.11 77 2.7 68 0.84 91 48 42 38 42 53 
173 51 153 49 20.9 18 15 300 2.2 78 1.8 81 0.79 112 61 58 64 58 71 
174 55 168 62 22 21 12 240 2.58 114 2.21 118 0.85 105 114 120 60 74 91 
 
 
 
                            PROFORMA 
NAME:                                                  AGE:           SEX:                   
STUDY NO.:    
ADDRESS: 
HEIGHT:                                  WEIGHT:                        BMI: 
HISTORY:                                AGE OF FIRST SMOKE: 
DURATION: 
SMOKING TYPE: CIGAR/ BEEDIES/CIGARETTS/ETS 
PACK YEARS: 
SMOKING INDEX: 
PRE EXISTING ILLNESS: 
PREMEDICATION: 
PFT: 
PARAMETER TRIAL 1 TRIAL 2 TRIAL 3 
FVCm    
FVCp    
FEV1m     
FEV1p    
FEV1 FVC m    
FEV1FVC p 
 
   
MEF 25- 75    
MEF 75    
MEF50    
MEF 25    
PEF    
 
GOLD STAGING: 
IMPRESSION: 
 
 
                                 ABBREVIATIONS 
a1AT – Alpha 1 Antitrypsin 
ABG – Arterial Blood Gas 
ATS – American Thoracic Society 
BMI – Body Mass Index 
COPD – Chronic Obstructive Pulmonary Disease 
ERS – Europian Respiratory Society 
ERV – Expiratory Reserve Volume 
ETS –  Environmental Tobacco Smoke 
FEV1 – Forced Expiratory Volume in one second 
FRC – Functional Residual Capacity 
FVC –Forced Vital Capacity 
GOLD –Global Initiative for Obstructive Lung Diseases 
HHIP –Hedgehog Interacting Protien 
IRV – Inspiratory Reserve Volume 
LHS – Lung Health Study 
MEF – Mid Expiratory Flow 
MMP 12 – Matrix Matelloprotienase 
PEF – Peak Expiratory Flow 
PEFR – Peak Expiratory Flow Rate 
RV – Residual Volume 
SI – Smoking Index 
TLC – Total Lung Capacity 
TPM – Total Particulate Matter 
 
 
TV – Tidal Volume 
VC – Vital Capacity 
V/Q – Ventilation Perfusion Ratio 
WHO – World Health Organization 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
